Involvement of granulocyte factor (GF) in receptor-triggered stimulation of lymphocytes and neutrophils.
Granulocyte factor derived from the specific granules of polymorphonuclear neutrophils affects mitogen--and alloantigen--induced proliferation of human lymphocytes "in vitro". A dual pattern of GF effect was noted: inhibition of mitogen induced lymphocyte proliferation in higher concentrations and costimulatory activity in lower concentrations of GF. GF induced the lymphocyte proliferation in combination with phorbol ester (PMA) or anti-CD2 monoclonal antibodies (mAb) with PMA. Other combinations of anti-CD2 and anti-CD3 mAb with GF do not augment the proliferation. The comitogenic activities of GF are associated with IL-2 production and IL-2R expression. Specific binding of labelled GF to stimulated lymphocytes suggests that it may recognize the specific molecule expressed only an activated cells. GF diminishes the zymosan-induced granulocyte stimulation, but GF acts as a stimulator of granulocyte O2 production. GF may recognize common targets on leukocytes. Leukocyte adhesive glycoproteins may be such putative targets.
Tchórzewski
H
H
Department of Pathophysiology and Immunology, Polish Academy of Sciences, Lódź, Poland.
Zeman
K
K
Sulowska
Z
Z
Kantorski
J
J
Cheng
R C
RC
Majewska
E
E
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology / Q000502:physiology; D001685:Biological Factors / Q000494:pharmacology*; D018801:CD2 Antigens; D017252:CD3 Complex; D002455:Cell Division / Q000187:drug effects; D006801:Humans; D007376:Interleukin-2 / Q000096:biosynthesis; D008163:Luminescent Measurements; D008213:Lymphocyte Activation / Q000187:drug effects; D008214:Lymphocytes / Q000187:drug effects*; D009504:Neutrophils / Q000187:drug effects*; D011948:Receptors, Antigen, T-Cell / Q000502:physiology; D011971:Receptors, Immunologic / Q000276:immunology; D015375:Receptors, Interleukin-2 / Q000096:biosynthesis; D015398:Signal Transduction / Q000187:drug effects; D013481:Superoxides / Q000378:metabolism; D016176:T-Lymphocyte Subsets / Q000187:drug effects; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D015054:Zymosan / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D000945:Antigens, Differentiation, T-Lymphocyte; D001685:Biological Factors; D018801:CD2 Antigens; D017252:CD3 Complex; D007376:Interleukin-2; D011948:Receptors, Antigen, T-Cell; D011971:Receptors, Immunologic; D015375:Receptors, Interleukin-2; D013481:Superoxides; D015054:Zymosan; D013755:Tetradecanoylphorbol Acetate